11月4日,来自加州圣地亚哥的生物科技公司 Viking Therapeutics, Inc.(VKTX)公布了其在研新型口服减肥药物VK2735的最新临床试验数据,结果令投资者振奋。
根据试验结果,服用100毫克剂量的VK2735后,肥胖患者在28天内平均减重8.2%,高于安慰剂组6.8个百分点。值得关注的是,在该剂量下,没有患者因不良反应而中断治疗,显示出VK2735具有良好的安全性和耐受性。这一数据预示着VK2735有望成为下一代有效且安全的口服减肥药。
目前减肥药市场主要被诺和诺德和礼来的注射剂产品所主导。如果VK2735能够顺利上市,将极大丰富病患的用药选择,为这一千亿级别市场带来新的竞争格局。分析师预计,VK2735更易服用、无需注射的特点或将令其成为病患首选,从而对注射剂产品形成挤压。彭博分析师肖表示:"Viking的药物疗效不错,同时也具备良好的安全性。"
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.